Biology Reference
In-Depth Information
Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR (2005) Bosentan decreases the plasma
concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol
60:107-112
Pauvert O, Bonnet S, Rousseau E, Marthan R, Savineau JP (2004) Sildenafil alters calcium
signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol
Lung Cell Mol Physiol 287:L577-L583
Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S (2007) An epidemiological study
of pulmonary arterial hypertension. Eur Respir J 30:104-109
Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Godot V, Capel F, Adnot S, Eddahibi S,
Mazmanian M, Fadel E, Herve P, Simonneau G, Emilie D, Humbert M (2007) Fractalkine-
induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 29:937-943
Phillips PG, Long L, Wilkins MR, Morrell NW (2005) cAMP phosphodiesterase inhibitors
potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J
Physiol Lung Cell Mol Physiol 288:L103-L115
Pyne NJ, Murray F, Tate R, MacLean MR (2007) Molecular determinants in pulmonary hyperten-
sion: the role of PDE5. CRC Press, Boca Raton
Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H (1994) Identification of PDE
isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266:
L536-L543
Raymond DR, Wilson LS, Carter RL, Maurice DH (2007) Numerous distinct PKA-, or EPAC-
based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4
coordination of cell adhesion. Cell Signal 19:2507-2518
Rybalkin SD, Bornfeldt KE (1999) Cyclic nucleotide phosphodiesterases and human arterial
smooth muscle cell proliferation. Thromb Haemost 82:424-434
Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG,
Beavo JA (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is
induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.
J Clin Invest 100:2611-2621
Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase
1C promotes human arterial smooth muscle cell proliferation. Circ Res 90:151-157
Rybalkina IG, Tang XB, Rybalkin SD (2010) Multiple affinity states of cGMP-specific phospho-
diesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent
mechanisms. Mol Pharmacol 77:670-677
Schafer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M (2009)
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-
ventricular remodelling. Cardiovasc Res 82:30-39
Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Leuchte H, Grimminger F, Seeger W,
Walmrath D (2001) Combination of nonspecific PDE inhibitors with inhaled prostacyclin
in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281:
L1361-L1368
Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N,
Schudt C, Ermert L, Seeger W, Grimminger F (2004) Antiremodeling effects of iloprost
and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental
pulmonary hypertension. Circ Res 94:1101-1108
Schermuly RT, Inholte C, Ghofrani HA, Gall H, Weissmann N, Weidenbach A, Seeger W,
Grimminger F (2005) Lung vasodilatory response to inhaled iloprost in experimental
pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir
Res 6:76
Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N,
Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A,
Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F (2007) Phosphodiesterase
1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
Circulation 115:2331-2339
